As with Ozempic (semaglutide) and Victoza (liraglutide), the significant increase in demand worldwide and the limited capacities of production sites have led to restrictions on the prescription of Trulicity. The supply is gradually improving and the Lilly laboratory announces the gradual resumption, from this month of October, of treatment initiations with Trulicity for patients with type 2 diabetes, in compliance with the recommendations of the National Agency for the Safety of Medicines and Health Products (ANSM). This measure has already been in effect since mid-September for Ozempic and Victoza.
However, to avoid the risk of stock shortages, a quota with limitation of the quantities distributed to wholesalers-distributors still remains in force. Continuous supply will be maintained through weekly distribution.
The laboratory recalls that any use of Trulicity for weight loss constitutes misuse leading to health risks and limits the access of diabetic patients to these essential treatments for them.
Yolande Gauthier
